Mirtazapine

This MedLibrary.org supplementary page on Mirtazapine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Mirtazapine
Systematic (IUPAC) name
2-methyl-1,2,3,4,10,14b- hexahydrobenzocpyrazino[1,2-a pyrido[3,2-fazepine
Identifiers
CAS number 61337-67-5
ATC code N06AX11
PubChem 4205
Chemical data
Formula C17H19N3 
Mol. mass 265.36
Pharmacokinetic data
Bioavailability 50%
Metabolism Liver
Half life 37 hours (females), 26 hours (males)
Excretion 75% urine 15% feces
Therapeutic considerations
Pregnancy cat.

C
Legal status

Prescription only
Routes Oral tablet, Soluble tablet

Mirtazapine is an antidepressant introduced by Organon International in 1994 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine and Maprotiline are the only tetracyclic antidepressants that have been approved by the U.S. Food and Drug Administration to treat depression. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic effects, serotonin-related side effects,[1] and adrenergic side effects (orthostatic hypotension and sexual dysfunction). Antihistaminic side effects of drowsiness and weight gain are prominent. It is most useful as an add-on medication to enhance the effectiveness of agents such as duloxetine and venlafaxine in severe and treatment-resistant depression. Mirtazapine is relatively safe if an overdose is taken.[2]

Contents

Trade names

Mirtazapine is marketed under the tradenames:

Indications

Approved use

Mirtazapine is primarily used to treat the symptoms of moderate to severe depression.[3]

Unapproved and off-label use

There is evidence that mirtazapine can be used to treat panic disorder (PD),[4] generalized anxiety disorder (GAD),[5] obsessive-compulsive disorder (OCD),[6] post traumatic stress disorder (PTSD)[7] sleep apnea,[8] and pruritus.[9] Mirtazapine has been reported to be effective in the prophylactic treatment of chronic tension headache.[10]

Veterinary use

Anecdotal evidence also suggests that mirtazapine may be effective in treating certain vomiting or anorexia-related conditions in dogs and cats. Any such use is still off-label, however.[11]

Mechanism of action

It is thought to work by blocking presynaptic Alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin, thereby increasing active levels in the synapse. Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors.

Side effects

Interestingly, its side-effect profile can be used for benefit in certain clinical situations. The drowsiness, increased appetite, and weight gain that it causes are useful in patients with depressive disorders with prominent sleep and appetite disturbances. In addition, it is quite useful in patient situations in which patients suffer from nausea, since it also antagonizes the 5-HT3 receptor, the target of the popular anti-emetic ondansetron (Zofran).

At lower doses, mirtazapine is primarily antihistaminergic, causing sedation, which can be beneficial in depressed patients who have difficulty falling asleep. Higher doses are generally less sedating as its antihistaminergic properties are thought to be offset by increased noradrenaline release.[12]

Side effects occurring commonly

Side effects occurring rarely

Dangerous side effects

Any of these side effects requires urgent medical attention. Medical advice is also required for taper-off instructions: sudden withdrawal from antidepressants can cause serious symptoms. However, sudden withdrawal can be used, under appropriate medical supervision, when the risks of continuing the antidepressant during a 'taper-off' phase are too great.

  • An allergic reaction; signs of swelling of the lips, face and tongue, difficulty in breathing, rash or itching (especially affecting the whole body) or feeling faint
  • Signs of infection such as fever, sore throat, mouth ulcers or stomach upset
  • Jaundice (yellowing of the skin and/or eyes)
  • Agranulocytosis

Withdrawal symptoms

An abrupt or overrapid reduction of antidepressants including mirtazapine can cause a discontinuation or withdrawal syndrome. Withdrawal symptoms may also occur in the neonate.[1] As with most antidepressants, a gradual and slow reduction in dose is recommended in order to minimize the discontinuation syndrome withdrawal effects.[2] Effects of sudden cessation of treatment may include:[3][4]

Dosage

Mirtazapine 30 mg tablets
Mirtazapine 30 mg tablets

The usual starting dose for mirtazapine is 15 mg once daily, usually at bedtime (because of its sedative nature and the possibility of disturbed visual perception). Doses may be increased, following medical advice, every 1-2 weeks up to a dose of 45 mg. It may be taken with or without food. Dispersible tablets (SolTab orally disintegrating tablets) can be taken without water.

Pregnancy and lactation

  • Pregnancy : Sufficient data in humans is lacking. The use should be justified by the severity of the condition to be treated.
  • Lactation : Sufficient data in humans is also lacking. Additionally, Mirtazapine may be found in the maternal milk in significant concentrations. The use in breastfeeding women should be carefully weighed against possible risks.

Interactions with other drugs

Because of the sedative effects of Mirtazapine, excessive sedation may result when it is used with other sedating substances, such as alcohol or benzodiazepines.

According to official prescribing information from Organon, Mirtazapine should not be used within 14 days of the use of an MAOI because of the risk of serious effects such as hypertensive emergency and hyperthermia.

References

  1. ^  Gillman, PK (2006). "A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status". Human Psychopharmacology Clinical and Experimental 21 (2): 117–25. doi:10.1002/hup.750. PMID 16342227. 
  2. ^  Burrows GD, Kremer CM. (1997). "Mirtazapine: clinical advantages in the treatment of depression". Journal of Clinical Psychopharmacology 17 (2S): 34S–39S. doi:10.1097/00004714-199704001-00005. PMID 9090576. 
  3. ^  Velazquez C, Carlson A, Stokes KA, Leikin JB. (2001). "Relative safety of mirtazapine overdose". Veterinary and Human Toxicology 43 (6): 342–344. PMID 11757992. 
  4. ^  Gorman JM (1999). "Mirtazapine: clinical overview". Journal of Clinical Psychiatry 60 (17): 9–13. PMID 10446735. 
  5. ^  Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology 19 (6): 567–596. doi:10.1177/0269881105059253. PMID 16272179. 
  6. ^  Goodnick PJ, Puig A, DeVane CL, Freund BV (1999). "Mirtazapine in major depression with comorbid generalized anxiety disorder". Journal of Clinical Psychiatry 60 (7): 446–448. PMID 10453798. 
  7. ^  Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005). "Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation". Journal of Clinical Psychiatry 66 (4): 515–520. PMID 15816795. 
  8. ^ "First Effective Drug For Sleep Disorder Identified". Science Daily (2003-06-05). Retrieved on 2008-05-01.
  9. ^  Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology 19 (6): 567–596. doi:10.1177/0269881105059253. PMID 16272179. 
  10. ^  Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. (2003). "Mirtazapine for pruritus". Journal of pain and symptom management 25 (3): 288–291. doi:10.1016/S0885-3924(02)00645-0. PMID 12614964. 
  11. ^  Bendtsen L, Jensen R (2004). "Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache". Neurology 62 (10): 1706–1711. PMID 15159466. 
  12. ^  Brooks DVM, DipABVP, Wendy C. (2007-04-30). "Mirtazapine (Remeron)". The Pet Pharmacy. Retrieved on 2008-03-06.
  13. ^  Nash J, Nutt D (2004). "Antidepressants". Psychiatry 6 (7): 289–294. 

Notes

  1. ^ Schwarzer, V; Heep, A; Gembruch, U; Rohde, A (Jan 2008). "Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine". Archives of gynecology and obstetrics 277 (1): 67–9. doi:10.1007/s00404-007-0406-5. PMID 17628816. 
  2. ^ Vlaminck, Jj; Van, Vliet, Im; Zitman, Fg (Mar 2005). "Withdrawal symptoms of antidepressants" (Free full text). Nederlands tijdschrift voor geneeskunde 149 (13): 698–701. ISSN 0028-2162. PMID 15819135. 
  3. ^ Benazzi, F (Jun 1998). "Mirtazapine withdrawal symptoms". Canadian journal of psychiatry. Revue canadienne de psychiatrie 43 (5): 525. ISSN 0706-7437. PMID 9653542. 
  4. ^ Berigan, Tr (Jun 2001). "Mirtazapine-Associated Withdrawal Symptoms: A Case Report" (PDF). Primary care companion to the Journal of clinical psychiatry 3 (3): 143. ISSN 1523-5998. PMID 15014614. PMC:181176. 
  5. ^ Klesmer, J; Sarcevic, A; Fomari, V (Aug 2000). "Panic attacks during discontinuation of mirtazepine". Canadian journal of psychiatry. Revue canadienne de psychiatrie 45 (6): 570–1. ISSN 0706-7437. PMID 10986577. 
  6. ^ Maccall, C; Callender, J (Oct 1999). "Mirtazapine withdrawal causing hypomania". The British journal of psychiatry : the journal of mental science 175: 390. ISSN 0007-1250. PMID 10789310. 
  7. ^ Ali, S; Milev, R (May 2003). "Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature". Canadian journal of psychiatry. Revue canadienne de psychiatrie 48 (4): 258–64. ISSN 0706-7437. PMID 12776393. 

External links

v • d • e
Psychoanaleptics: antidepressants (N06A)
MAOIs
RIs
SSREs
AAs
Tetras (Mianserin, Mirtazapine)
v • d • e
Adrenergic antagonists
α
Non-selective α
reversible (Phentolamine) · irreversible (Phenoxybenzamine)
Ungrouped
β
β1 selective
(cardioselective)
Mixed α1/β
Indirect
tyrosine hydroxylase inhibitor (Metirosine) · vesicle storage inhibitor (Reserpine) · neurotransmitter release blocker (Guanethidine, Bretylium)

Wikipedia content modification information:

  • This page was last modified on 25 September 2008, at 15:45.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Mirtazapine".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.